Cargando…

IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy

Th9 cells are powerful effector T cells for cancer immunotherapy. However, the underlying antitumor mechanism of Th9 cells still needs to be further elucidated. Here, we show that Th9 cells express high levels of not only IL-9, but also IL-24. We found that knockout of Il24 gene in Th9 cells promote...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jintong, Zhang, Yunwei, Zhang, Hua, Zhang, Mingyue, Dong, He, Qin, Tianxue, Gao, Sujun, Wang, Siqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480301/
https://www.ncbi.nlm.nih.gov/pubmed/37680459
http://dx.doi.org/10.1016/j.isci.2023.107531
_version_ 1785101765105942528
author Chen, Jintong
Zhang, Yunwei
Zhang, Hua
Zhang, Mingyue
Dong, He
Qin, Tianxue
Gao, Sujun
Wang, Siqing
author_facet Chen, Jintong
Zhang, Yunwei
Zhang, Hua
Zhang, Mingyue
Dong, He
Qin, Tianxue
Gao, Sujun
Wang, Siqing
author_sort Chen, Jintong
collection PubMed
description Th9 cells are powerful effector T cells for cancer immunotherapy. However, the underlying antitumor mechanism of Th9 cells still needs to be further elucidated. Here, we show that Th9 cells express high levels of not only IL-9, but also IL-24. We found that knockout of Il24 gene in Th9 cells promotes Th9 cell proliferation in vitro, but decreases Th9 cell survival in vitro and in vivo. Interestingly, knockout of Il24 gene in Th9 cells decreases the tumor-specific cytotoxicity of Th9 cells in vitro. In addition, immunotherapy with Il24 knockout Th9 cells exhibit less tumor inhibition than regular Th9 cells in mouse tumor models. We found that inhibition of Foxo1 by a specific inhibitor downregulates IL-24 expression in Th9 cells and decreases Th9 cell antitumor efficacy in vivo. Our results identify IL-24 as a powerful antitumor effector of Th9 cells and provide a target in Th9 cell-mediated tumor therapy.
format Online
Article
Text
id pubmed-10480301
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104803012023-09-07 IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy Chen, Jintong Zhang, Yunwei Zhang, Hua Zhang, Mingyue Dong, He Qin, Tianxue Gao, Sujun Wang, Siqing iScience Article Th9 cells are powerful effector T cells for cancer immunotherapy. However, the underlying antitumor mechanism of Th9 cells still needs to be further elucidated. Here, we show that Th9 cells express high levels of not only IL-9, but also IL-24. We found that knockout of Il24 gene in Th9 cells promotes Th9 cell proliferation in vitro, but decreases Th9 cell survival in vitro and in vivo. Interestingly, knockout of Il24 gene in Th9 cells decreases the tumor-specific cytotoxicity of Th9 cells in vitro. In addition, immunotherapy with Il24 knockout Th9 cells exhibit less tumor inhibition than regular Th9 cells in mouse tumor models. We found that inhibition of Foxo1 by a specific inhibitor downregulates IL-24 expression in Th9 cells and decreases Th9 cell antitumor efficacy in vivo. Our results identify IL-24 as a powerful antitumor effector of Th9 cells and provide a target in Th9 cell-mediated tumor therapy. Elsevier 2023-08-03 /pmc/articles/PMC10480301/ /pubmed/37680459 http://dx.doi.org/10.1016/j.isci.2023.107531 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Chen, Jintong
Zhang, Yunwei
Zhang, Hua
Zhang, Mingyue
Dong, He
Qin, Tianxue
Gao, Sujun
Wang, Siqing
IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy
title IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy
title_full IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy
title_fullStr IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy
title_full_unstemmed IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy
title_short IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy
title_sort il-24 is the key effector of th9 cell-mediated tumor immunotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480301/
https://www.ncbi.nlm.nih.gov/pubmed/37680459
http://dx.doi.org/10.1016/j.isci.2023.107531
work_keys_str_mv AT chenjintong il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy
AT zhangyunwei il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy
AT zhanghua il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy
AT zhangmingyue il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy
AT donghe il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy
AT qintianxue il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy
AT gaosujun il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy
AT wangsiqing il24isthekeyeffectorofth9cellmediatedtumorimmunotherapy